Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: Emerging opportunities in oxidative damage and autophagy

Current Molecular Medicine

Volumn 12, Issue 6, 2012, Pages 763-771

  Dickey, J S ^a   Rao, V A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Autophagy; Doxorubicin; Oxidative stress; Protein oxidation; Reactive oxygen species; Troponin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; APOLIPOPROTEIN A1; ARSENIC TRIOXIDE; ASPARAGINASE; BIOLOGICAL MARKER; BLEOMYCIN; BRAIN NATRIURETIC PEPTIDE; CARBONYL DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME C; DOXORUBICIN; FLUOROURACIL; GAMMA H2AX PROTEIN; HISTONE H2AX; IMATINIB; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MALONALDEHYDE; METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE (ACYLATING); MITOMYCIN; MITOXANTRONE; PEROXIREDOXIN 1; SUNITINIB; TRANSCRIPTION FACTOR NRF2; TROPONIN C; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 2;

APOPTOSIS; ARTICLE; AUTOPHAGY; BLOOD LEVEL; BRADYCARDIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL SURVIVAL; DISEASE MARKER; DNA ADDUCT; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIA; LIPID PEROXIDATION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; QT PROLONGATION; SCINTIANGIOGRAPHY; THROMBOEMBOLISM;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84862526571     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800792561     Document Type: Article

References (103)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1: 1-48.
3. Kinders RJ, Hollingshead M, Lawrence S, et al. Development of a validated immunofluorescence assay for gammaH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res 2010; 16: 5447-57.
4. Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, Bonner WM. Recent developments in the use of gamma- H2AX as a quantitative DNA double-strand break biomarker. Aging 2011; 3: 168-74.
5. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Seminars in Oncology 2006; 33: S8-14.
6. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med 2006; 57: 485-98.
7. Broeyer FJ, Osanto S, Ritsema van Eck HJ, et al. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 2008; 134: 961-8.
8. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14: 162-7.
9. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supraadditive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49: 1486-93.
10. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010; 53: 105-13.
11. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 2010; 28: 1276-81.
12. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-15.
13. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14-25.
14. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.
15. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191-6.
16. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2: 251-6. discussion 9-61, 64-6.
17. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Exp RevAnticancer Ther 2006; 6: 1249-69.
18. van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004; 40: 643-52.
19. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-91.
20. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-12.
21. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993: 117-30.
22. Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475-84.
23. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374-8.
24. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5- fluorouracil. Pharmacotherapy 1997; 17: 729-36.
25. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-4.
26. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-53.
27. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-48.
28. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37: 300-11.
29. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-6.
30. Verweij J, Funke-Kupper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988; 5: 159-63.
31. Creech RH, Catalano RB, Shah MK, Dayal H. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer 1983; 51: 1034-40.
32. White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987; 59: 1582-5.
33. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-23.
34. Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 54: 330-4.
35. Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011: 14-32.
36. Fragasso G, Pastore MR, Vicari A, Chierchia SL, Pozza G. Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Am J Hematol 1995; 48: 136-7.
37. Saviola A, Luppi M, Potenza L, et al. Myocardial ischemia in a patient with acute lymphoblastic leukemia during Lasparaginase therapy. Eur J Haematol 2004; 72: 71-2.
38. Choueiri TK, Mayer EL, Je Y, et al. Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. J Clin Oncol 2011: 632-8.
39. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000; 102: 272-4.
40. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumabinduced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-6.
41. Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP, Coleman RE. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 2010; 19: 339-44.
42. Hasinoff BB, Chee GL, Thampatty P, Allan WP, Yalowich JC. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecinmediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs 1999; 10: 47-54.
43. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: longterm follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950-61.
44. Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJ. Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol 1985; 59: 1298-303.
45. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 1986; 261: 3068-74.
46. Gervasi PG, Agrillo MR, Lippi A, Bernardini N, Danesi R, Del Tacca M. Superoxide anion production by doxorubicin analogs in heart sarcosomes and by mitochondrial NADH dehydrogenase. Res Commun Chem Pathol Pharmacol 1990; 67: 101-15.
47. Doroshow JH, Davies KJ. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)- methanesulfon-m-anisidide, and neocarzinostatin. Biochem Pharmacol 1983; 32: 2935-9.
48. Davies KJ, Doroshow JH, Hochstein P. Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin. FEBS Lett 1983; 153: 227-30.
49. Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 2001; 97: 2839-45.
50. Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 1981; 29: 1393-401.
51. Velez JM, Miriyala S, Nithipongvanitch R, et al. p53 Regulates Oxidative Stress-Mediated Retrograde Signaling: A Novel Mechanism for Chemotherapy-Induced Cardiac Injury. PLoS One 2011; 6: e18005.
52. Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008; 51: 327-33.
53. Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 2008; 25: 655-64.
54. Horacek JM, Pudil R, Tichy M, et al. Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie 2008; 31: 559-60.
55. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008; 130: 688-95.
56. Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat 2008; 40: 121-6.
57. Ziech D, Franco R, Georgakilas AG, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chem Biol Interact 2010; 188: 334-9.
58. Kobayashi S, Susa T, Tanaka T, et al. Urinary 8-hydroxy-2'- deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 29-36.
59. Biniecka M, Kennedy A, Fearon U, Ng CT, Veale DJ, O'Sullivan JN. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis 2010; 69: 1172-8.
60. Haghdoost S, Maruyama Y, Pecoits-Filho R, et al. Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation? Antioxid Redox Signal 2006; 8: 2169-73.
61. Sander CS, Chang H, Salzmann S, et al. Photoaging is associated with protein oxidation in human skin in vivo. J Invest Dermatol 2002; 118: 618-25.
62. De Maria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21: 291-5.
63. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67: 8839-46.
64. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010; 704: 152-9.
65. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma 2009; 118: 683-92.
66. Suhail N, Bilal N, Khan HY, et al. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J Clin Pharm Ther 2011. [epub ahead of print].
67. Senturker S, Tschirret-Guth R, Morrow J, Levine R, Shacter E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch Biochem Biophys 2002; 397: 262-72.
68. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa M, et al. Does chemotherapy-induced oxidative stress improve the survival rates of breast cancer patients? Antioxid Redox Signal 2011; 15(4): 903-9.
69. Suddek GM. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chemother Pharmacol 2010.
70. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-23.
71. Wu T, Rifai N, Roberts LJ, 2nd, Willett WC, Rimm EB. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomarkers Prev 2004; 13: 1399-402.
72. Stadtman ER, Levine RL. Protein oxidation. Ann N Y Acad Sci 2000; 899: 191-208.
73. Levine RL, Wehr N, Williams JA, Stadtman ER, Shacter E. Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 2000; 99: 15-24.
74. Levine RL, Moskovitz J, Stadtman ER. Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation. IUBMB Life 2000; 50: 301-7.
75. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429-37.
76. Dalle-Donne I, Scaloni A, Giustarini D, et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005; 24: 55-99.
77. Polidori MC, Griffiths HR, Mariani E, Mecocci P. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids 2007; 32: 553-9.
78. Iorio A, Federici MO, Mourvaki E, et al. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Thromb Haemost 2007; 98: 635-41.
79. Levine RL, Stadtman ER. Oxidative modification of proteins during aging. Exp Gerontol 2001; 36: 1495-502.
80. Nystrom T. Role of oxidative carbonylation in protein quality control and senescence. Embo J 2005; 24: 1311-7.
81. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-76.
82. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000; 33 Suppl: S99-108.
83. Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal 2003; 5: 577-82.
84. Agarwal R. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol 2005; 288: F265-71.
85. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18: 815-21.
86. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233: 346-57.
87. Kumar SN, Konorev EA, Aggarwal D, Kalyanaraman B. Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. J Proteomics 2011; 74: 683-97.
88. Dekkers DH, Bezstarosti K, Gurusamy N, et al. Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. J Cell Mol Med 2008; 12: 1677-89.
89. Miyata T, Takizawa S, van Ypersele de Strihou C. Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets. Am J Physiol Cell Physiol 2011; 300: C226-31.
90. Rao VA, Klein SR, Bonar SJ, et al. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem 2010; 285: 34447-59.
91. Scherz-Shouval R, Shvets E, Elazar Z. Oxidation as a posttranslational modification that regulates autophagy. Autophagy 2007; 3: 371-3.
92. Klamt F, Zdanov S, Levine RL, et al. Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol 2009; 11: 1241-6.
93. Aluise CD, Miriyala S, Noel T, et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: Implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 2011.
94. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213-23.
95. Crisan TO, Plantinga TS, van de Veerdonk FL, Farcas MF, Stoffels M, Kullberg BJ, et al. Inflammasome-independent modulation of cytokine response by autophagy in human cells. PLoS One 2011; 6: e18666.
96. Butterfield DA, Sultana R. Identification of 3-nitrotyrosinemodified brain proteins by redox proteomics. Methods Enzymol 2008; 440: 295-308.
97. Banerji U, de Bono J, Judson I, Kaye S, Workman P. Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 2008; 14: 2512. author reply 3-4.
98. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010; 102: 152-60.
99. Qualification Process for Drug Development Tools. FDA Guidance for Industry 2010.
100. Goodsaid FM, Mendrick DL. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010; 2: 47ps4.
101. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009; 158: 317-26.
102. Clements P, Brady S, York M, Berridge B, Mikaelian I, Nicklaus R, et al. Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicol Pathol 2010; 38: 703-14.
103. Issaq HJ, Waybright TJ, Veenstra TD. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods. Electrophoresis 2011; 32: 967-75.